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Abstract: Considering nanogels, we have focused our attention on hybrid nanosystems for drug
delivery and biomedical purposes. The distinctive strength of these structures is the capability to join
the properties of nanosystems with the polymeric structures, where versatility is strongly demanded
for biomedical applications. Alongside with the therapeutic effect, a non-secondary requirement of
the nanosystem is indeed its biocompatibility. The importance to fulfill this aim is not only driven by
the priority to reduce, as much as possible, the inflammatory or the immune response of the organism,
but also by the need to improve circulation lifetime, biodistribution, and bioavailability of the carried
drugs. In this framework, we have therefore gathered the hybrid nanogels specifically designed
to increase their biocompatibility, evade the recognition by the immune system, and overcome the
self-defense mechanisms present in the bloodstream of the host organism. The works have been
essentially organized according to the hybrid morphologies and to the strategies adopted to fulfill
these aims: Nanogels combined with nanoparticles or with liposomes, and involving polyethylene
glycol chains or zwitterionic polymers.
Keywords: nanogels; nanohybrids; stealth nanoparticles; biocompatible carriers; drug delivery;
PEGylation; zwitterionic polymers; nanolipogels
1. Introduction
Among the different polymeric biomaterials studied for application in nanomedicine,
a considerable interest is focused on nanogels [1–4]. These constructs can be described as soft
polymeric nanoparticles designed to be stable in a liquid media, typically aqueous, as a dispersed
phase. The polymer of the particles is crosslinked, and in the presence of a solvent, these swell turn
into stable “jelly” nanoparticles [5]. Such nanostructures are extensively exploited to prepare drug
delivery system [6,7] due to their compatibility with the physiological environment [8,9], capability
to host drug molecules in their polymeric network [10], and of course, for the adaptability of the
involved polymers [11]. The particles can be easily decorated, modified, and functionalized to prepare
a very wide variety of architectures [12]. Moreover, due to their versatility, a significant portion of
studies concern nanohybrids obtained through their conjugation with other types of nanoparticle and
nanostructures, both organic [13] and inorganic [14]. This approach has been studied for many years
for nanomedicine application [15], since it allows for the exploitation of the properties derived from
the nanoparticles maintaining the characteristics of the nanogel. Several types of particles are involved
in hybrid nanogels: Gold nanoparticle [16], carbonaceous materials [17], liposomes [18], quantum
dots [19], and magnetic nanoparticles [20–22] are just the most common examples.
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The morphologies of hybrid nanogels may be multiple, according to the type of involved
particles and to the assembly technique [23,24]. Frequently, the nanoparticles represent the core of
the hybrid, surrounded by a polymer shell [25–27] or homogeneously embedded in the polymer
network [28,29]; in other cases, instead, the polymeric structures are themselves assembled in
core-layer-shell geometries [30]. The sizes may vary according to the nanohybrid type and to the
dimensions of the involved particles, however, as described below, the typical overall range is between
50 and about 400 nm. These morphologies are qualitatively represented in Figure 1. It should be noted,
however, how even further combinations are appreciable in the literature [31,32].
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remain the most pursued approach [36–39]. This class of reactions typically exploits the reactivity of 
acrylates or vinyl groups, allowing an easy variation of the monomers and crosslinker without 
substantially redesigning the reaction conditions. In addition, the possibility to choose, among many 
different types of monomers, favors the selection of the most appropriate functional group for the 
desired properties [26,40,41]. The polymer network can also be obtained through physical 
crosslinking. In this case, although the preparation and stability of physical non-covalent nanogels 
may be more difficult to control or predict, there are still valid examples based on hydrogen bond 
[42–44], ionic interactions [45–47], and other intermolecular bonds [48–50]. In summary, the overall 
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the interactions with the host environment [51,52], and through a fine design of the structure [53]. 
Nanostructured drug delivery systems are mostly devised for the cancer treatment through 
parenteral administration, as the intravenous or the intradermal route [54,55]. Other types of 
administration like oral, topical, inhalation, and so on, indeed also offers physical barriers to 
overcome prior to reaching the target; nevertheless, even in trough systemic or local injection, hurdles 
are still multiple. When a nanoparticle enters a living organism, one of the first factors to consider 
should be the interaction between the components of blood stream, especially those belonging to 
immune system, and the nanoparticle’s surface [56,57]. In this regard, several authors draw the 
attention on the biocorona, an ensemble of proteins and biomolecules that entirely wrap the 
nanoparticles as these enter the organism, deemed to be the true entity involved in physiological 
interactions [58]. The result of bio/protein corona formation is a new nano-object which biological 
fate might be influenced only marginally by the original nanoparticle’s features [59]. In this 
background, a proper surface decoration, together with a control over dimensions, seems to be a 
parameter capable of strongly influencing the biodistribution [60–63]. In any case, the issues are 
various: Sequestration from the circulation operated by the immune system (opsonization), early 
clearance, poor pharmacokinetic, and eventually the accumulation far from the desired site of action 
[64–66]. Moreover, a lack of biocompatible surface could induce the host organism to develop 
inflammatory responses to the introduced substance [67]. As a further concern, although the 
considered decoration may be mainly aimed to improve the biodistribution/biocompatibility of the 
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To prepare such nanohybrids, many types of reactions may be adopted [33], typically carried
out in the dispersed phase [34,35]. However, the radical polymerizations, free or controlled, probably
remain the most pursued approach [36–39]. This class of reactions typically exploits the reactivity
of acrylates or vinyl groups, allowing an easy variation of the monomers and crosslinker without
substantially redesigning the reaction conditions. In addition, the possibility to choose, among many
different types of monomers, favors the selection of the most appropriate functional group for the
desired properties [26,40,41]. The polymer network can also be obtained through physical crosslinking.
In this case, although the preparation and stability of physical non-covalent nanogels may be more
difficult to control or predict, there are still valid examples based on hydrogen bond [42–44], ionic
interactions [45–47], and other intermolecular bonds [48–50]. In summary, the overall purpose of
hybrid nanogels is to protect the loaded drug and perform a tailored delivery by tuning the interactions
with the host environment [51,52], and through a fine design of the structure [53].
Nanostructured drug delivery systems are mostly devised for the cancer treatment through
parenteral administration, as the intravenous or the intradermal route [54,55]. Other types of
administration like oral, topical, inhalation, and so on, indeed also offers physical barriers to overcome
prior to reaching the target; nevertheless, even in trough systemic or local injection, hurdles are still
multiple. When a nanoparticle enters a living organism, one of the first factors to consider should
be the interaction between the components of blood stream, especially those belonging to immune
system, and the nanoparticle’s surface [56,57]. In this regard, several authors draw the attention on
the biocorona, an ensemble of proteins and biomolecules that entirely wrap the nanoparticles as these
enter the organism, deemed to be the true entity involved in physiological interactions [58]. The result
of bio/protein corona formation is a new nano-object which biological fate might be influenced only
marginally by the original nanoparticle’s features [59]. In this background, a proper surface decoration,
together with a control over dimensions, seems to be a parameter capable of strongly influencing the
biodistribution [60–63]. In any case, the issues are various: Sequestration from the circulation operated
by the immune system (opsonization), early clearance, poor pharmacokinetic, and eventually the
accumulation far from the desired site of action [64–66]. Moreover, a lack of biocompatible surface
could induce the host organism to develop inflammatory responses to the introduced substance [67].
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As a further concern, although the considered decoration may be mainly aimed to improve the
biodistribution/biocompatibility of the particle, even the matter related to the ligands interaction
with cancer tissues should be taken into account [68]. Then, considering the role of the dimensions,
nanoparticles smaller than 10–20 nm appear to be quickly removed by renal clearance, while those
larger than 120–150 nm would be captured by the liver and spleen [69,70]. Even surface charge (zeta)
has been identified among the factors affecting the circulating time and the in vivo behavior [71].
Despite various opinions, data suggest that a small negative charge or a neutral surface could be the
best conditions to prolong the circulating time of nanostructures [64,72,73].
Concerning hybrid nanogels, we reviewed here the different nanohybrids equipped with
functionalizations or strategies tailored to tackle the opsonization and the unfavorable conditions of a
living system. For the drug delivery, we actually consider a critical challenge to the development of
stealth systems, namely, carriers endowed of the broadest biocompatibility towards the organism or
even invisibles to its immune system. The considered hybrid nanogels, whose main morphologies are
schematized in Table 1, have therefore been grouped according to the strategy adopted, examining
in vitro and in vivo results, approaches, and structures devised to fulfill the aim of biological
compatibility. To the state of the art, many stealth functionalizations exploit hydrophilic polymeric
chains as polyethylene glycols or chitosan. Nevertheless, in addition to the preparation and decoration
methods, the limits of this approach will also be briefly discussed. Even more recent examples, such
as zwitterionic polymers and liposome-embedded structures, seem to provide satisfactory stealth
properties and have been properly considered.
Pharmaceutics 2019, 11, 71 4 of 24
Table 1. The main morphologies of the described nanogels with summarized the biological outcomes.
Schematized Structure of the Hybrid Stealth Strategy Size Biological Results Reference
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2. Polyethylene Glycol Decoration
The surface decoration with polyethylene glycol (PEG) chains, termed PEGylation, was one of the
earliest methods employed to provide biocompatibility to nanomaterials entering the organism [86].
This is also the most adopted one on clinically approved drugs, and could be considered as a benchmark
of stealth decoration [87]. On nanogels, PEGylated systems have been adopted for many years with
appreciable results on drug delivery application [88]. The successful mechanisms of PEGylation
may be due to multiple factors: PEG hydrophilic chains, typically with Mw between 2.000 and
13.000 Da [89], create a hindered zone around the nanoparticle that reduce the wrapping by plasma
proteins and the subsequent uptake by macrophages [90]. Another main effect is related to the
high hydrophilicity acquired by the particle surface, less susceptible to antibody recognition [91].
This effect is even described as the formation of an aqueous layer that disguise the structure from
the opsonization processes [92]. According to the ligand density and polymer sizes, the chains
may assume different spatial dispositions (e.g., “mushroom” or “brush”). Nevertheless, a high
density [93] and lengths of at least of 5 kDa seem to provide better outcomes [94]; overall, the observed
effect of PEGylation is to increase the bioavailability of decorated nanostructures by extending the
circulating lifetime [95]. Thanks to the numerous studies, it was also possible to identify other
effects arising from this decoration; authors observed variations in the drug release rate [96] or
even an improvement of the uptake by cancer cells due to a specific protein corona, formed around
the antifouling PEG functionalization [73]. Other works suggest the adoption of cleavable chains,
detachable after endocytosis, to speed up the endosomal escape [90]. Such an effect is also to remove it
from the particles possible obstacles to the cellular internalization, once these are extravasated from
blood vessels [97]. Another discovered effect, actually related to the extended circulating lifetime, is
the rise of an immune response PEG-specific. This was observed with repeated administration of the
compound, which resulted in liver and spleen accumulation, in addition to a rapid clearance of the
material [98].
A pioneer effort on hybrid PEGylated nanogel should be credited to Nagasaki and coworkers,
who have been developing, for several years, hybrid nanogels incorporating gold nanoparticles
in the polymer. In an early work [99], they prepared acrylate pH-sensitive nanogels introducing
the PEG decoration (Mw = 8000 Da) through the comonomer PEG-styrene in the radical emulsion
polymerization. While the compound is yet to contain gold and cannot be considered hybrid, it is worth
mentioning that biological tests showed absence of toxicity on MCF-7 and HuH-7 cells. Afterwards,
they developed a hybrid gold nanoparticle-gel through permeation of HAuCl4 in the polymer core
and successive self-reduction of the metal, triggered by the amino groups [100] (Figure 2); in this case,
the PEGylation was achieved adding PEG-methacrylate as the initial comonomer. The nanohybrid
shows a diameter near 70 nm at neutral pH, evaluated by Dynamic Light Scattering (DLS).
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Figure 3. The PEGylated nanogel containing gold nanoparticles and fluorescein isothiocyanate-
labeled peptides.
In solution, due to the presence of gold nanoparticles, the nanohybrid shows the quenching of the
FITC fluorescence. Upon internalization into cancer cells, instead, the presence of caspase-3 cleaves
the peptide releasing the FITC and restoring the fluorescence. In vitro results have been carried out on
HuH-7 hepatocarcinoma cell line, evidencing the role of PEGylation in providing a gel without the
typical biocompatibility issues of polyamine. To extend the work, the research group prepared another
nanogel for the encapsulation of gold nanoparticles as a photothermal device against HeLa carcinoma
cells [75]. In the absence of laser irradiation, no toxicity was observed for the PEGylated nanogel, even
at concentrations up to 480 µg/mL. However, authors show that the toxicity rises up as the crosslinking
density decreases, the toxicity rises up, ascribing this result to the exposure of the polyamine branches.
This effect is also reported in a work on PEGylated polyamine acrylic nanogel [101], in which the
reduced biocompatibility is attributed to an insufficient length of PEG chains (1500 instead of 8000 Da).
In the successive years, although without biological tests, Nagasaki et al. also successfully incorporated
silica/gold nanoparticles in the nanogel network [102,103]. Eventually, such a nanohybrid was also
adapted to prepare a radiosensitizer agent, exploiting the presence of the gold nanoparticles in the
polymer [104].
A comparable system prepared by Claverie et al., embedded PEGylated acrylic nanogel with
gold nanoparticle [76] and consolidates the previous results. In this case, authors evaluate the effect of
various reaction parameters such as initiators, cross-linkers, monomers ratio, PEG concentration, and
Mw on thermoresponsive responsive properties and on the nanogel structure. The dimensions of the
prepared particles thus range from 52 to about 350 nm. Even if biological tests were not performed, the
work also dedicates a large effort in investigating the core-shell structure of nanoparticles, evidencing
the presence of PEG chains in the outer layer through techniques of differential scanning calorimetry
and Transmission Electron Microcopy (TEM, Figure 4).
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The inner structure of these particles is instead constituted by the diethylaminoethyl methacrylate
polymer, confirming the description of Nagasaki [74]. Various PEG methacrylate in the Mw range of
500–4000 Da were selected to evaluate the effect of chain lengths; data show that, typically, shorter
PEG chains bring to larger particles, and the shortest PEG chain (~ 500 Da) is indeed unable to stabilize
the monomer droplets, yielding a non-uniform size distribution of nanoparticles. Additionally, various
concentrations of the PEG monomer were tried, finding the main outcomes at the polymerization stage:
Increasing the content of PEG acrylate decreases the size of the nanogel particle. This is reasonably
due to the stabilizing effect of PEG chains towards smaller particles in the emulsion polymerization
process. Gold nanoparticles were eventually inserted by in situ reduction of HAuCl4 to demonstrate
the capability of the nanogel to host metal nanoparticles.
Zhou et al. prepared a noteworthy example of core-shell PEGylated nanogel, with a nucleus of
Au/Ag, a hydrophobic inner polymer, and a crosslinked PEG shell [77] (scheme in Figure 5).
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Figure 6. Graphic representation of PEG-chitosan-(carbon dots) hybrid nanogel [78].
The nanogel also shows fluorescence, upon irradiation at 405 nm, due to the presence of
incorporated carbon dots. The fluorescent behavior, the biocompatibility, and the cytotoxic efficacy
have been tested by in vitro experiments on human prostate cancer cells DU145 (up to 100 µg/mL of
nanohybrid) and in vivo on mice models to evaluate the possible animal toxicity. The permanence of
the fluorescence was observed, and a strong decrease on the cellular viability was detected upon NIR
irradiation of the drug-loaded system. The in vivo biocompatibility of the nanohybrid was proven by
direct comparison between C57BL/6 mice injected with the drug free nanogel and non-injected animals.
The histopathological data showed renal and hepatic tissues without signs of toxicity, confirming the
in vitro results. The synergistic effect of doxorubicin and hyperthermia was also proved.
Crosslinked polymeric micelles as system for the co-delivery of different drugs, have been
prepared by Bronich and her research group [30]. This nanogel is composed by a block
copolymer of polyethylene glycol-polyglutamic acid-polyphenylalanine that confers a hybrid structure
core–layer–shell with PEG in the external zone (Figure 7).
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It is worth oting how this effect occurs only when the two drugs are present together on t e sa e
a ogel article. This assumption arises from comparative experiments performed incubating the cells
in co-presence of paclitaxel and cisplatin, but with the drugs loaded n separate articles. The in vivo
experiments confirmed the synergistic effect and showed higher accumulation of the drug in the
tumoral tissue. Results also evidence the absence of histopat ological changes, respect to untreated
a imals, in the kidney tissue of animals treated with the nanogel. I particular, authors underline
how the lower nephrotoxicity might represent a strong advancement concerning the use of this drug,
considerin how the renal t xicity co stitutes the side effect t at most restrict cisplatin therapies [105].
Another evidenced effect of this drug delivery system is the higher platinum accumulation in spleen
nd liver, although the value is greatly reduced after a month, and no signs of splenic or hepatic
toxicity were detectable. Even still, through histopathologic analyses, t e nanogel particles inside t e
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spleen were only localized in the red pulp and poorly in lymphoid regions, suggesting the absence of
free drug in these areas and providing a possible rationale for the absence of splenotoxicity.
3. Nanogels inside Liposomes: Nanolipogels
A quite different type of nanohybrids can be obtained combining nanogel particles with liposomes.
In these structures, named nanolipogels, liposomes act as templates to host the nanogel in their internal
compartment and remaining after polymerization as an external lipidic shell. As a further effect, the
presence of the gel in the core imparts stability to the whole nanostructure. On these nanohybrids,
a stealth strategy can be achieved simply preparing liposomes with PEGylated phospholipids.
While polymers embedded in liposomes have been studied for some years [18], nanogels (i.e.,
crosslinked polymers) are only present in few cases. However, the various publications, herein
described, show a positive combination of nanogels with stealth liposomes.
An appreciable milestone of these nanohybrids may be represented by the work of Fahmy and
colleagues [79], who have prepared and tested in vivo on a nanoscale liposomal polymeric gel that can
release simultaneously hydrophilic and hydrophobic compounds. The liposomes were prepared, along
with phosphatidylcholine and cholesterol, with an aliquot of PEGylated phosphatidylethanolamine
(Mw of PEG = 2000 Da) in order to present a stealth surface; the final structure show a diameter
of 120 nm and a near zero zeta potential. The inner nanogel is based on a bisacrylate-terminated
PEG–lactide bioresorbable macromonomer (Mw ~ 4000 Da) polymerized via an UV-activated initiator
(Figure 8).
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The incorporation of the nanogel involves the reconstitution of lyophilized liposomes in a
precursor solution containing acrylate macromonomers and initiator. The suspension is then diluted
five times to avoid massive gelation outside the liposomes and eventually exposed to UV light for the
nanogel curing. The loading of the drugs into nanogel occurs by introducing in the precursor solution
of the two substances: Transforming growth factor-β inhibitor (SB505124, Figure 8, commercially
available, denoted SB) and interleukin-2 (a 15 kDa signaling protein belonging to the immune
system [106]). These two compounds were chosen specifically for their individual pharmacological
properties, to assess the synergistic anticancer effect by increasing the activity of natural killer cells.
The molecule SB, for an optimal encapsulation and a sustained release, has been previously inserted
in a cyclodextrin derivative bearing acrylic groups (Figure 8 together with the complete structure).
The overall outcome of this nanohybrid was thus the simultaneous and localized release of the two
drugs. Since numerous pharmacokinetic data of this PEGylated structure have been collected, we
deemed appropriate to detail the main outcomes. In vivo experiments on murine models monitored
the biodistribution, safety, and toxicological profile of the fully laden platform as well as of the empty
system, adopting animals administered with PBS as control. These have provided useful information
on circulation lifetime, possible secondary effects, and accumulation sites. Specific tests were also
performed to evaluate the passive infiltration capability of this delivery system inside the tumoral
microenvironment with respect to peritumoral tissue. Acute toxicity was evaluated seven days after
a single intravenous dose of the nanolipogel: The blood parameters showed values within normal
physiological ranges, absence of detectable hepatotoxicity, absence of renal toxicity, and absence of
hematic toxicity. Lungs were screened by histological analysis revealing no signs of pulmonary toxicity.
In addition, markers for inflammatory responses revealed no statistical differences with respect to
control animals administered with phosphate buffered solution (PBS). Biodistribution, pursued by
loading the nanolipogel with rhodamine, displayed an increased persistence in the blood stream, with
a 24 h post-injection concentration of about 8% of the initial dose. The residual rhodamine at 1 h
post-injection time is no more detectable, while the residual nanolipogel at the same time lapse is
~16% (Figure 9a). The analysis of organs showed the primary accumulation of rhodamine in liver,
kidney, and lungs (Figure 9b), with a higher level for the encapsulated substance. The mediated
delivery, valued after an injection nearby the tumor microenvironment, revealed a sustained release of
rhodamine, with a migration from the peritumoral area to the tumoral mass, and a final accumulation
in the inner region of around 25% of the administered dose (Figure 9c).
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all plots represent ± std. dev. Reprinted by permission from Springer Nature: Nature Materials [79],
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The therapeutic effects were analyzed on B16/B6 murine melanoma model: Experiments were
performed on single tumors and on metastatic ones, respectively, managed with local and systemic
treatment; achievements were consistent with the pharmacokinetics data.
Another relevant example from the same research group presents the preparation of nanolipogels
for the treatment of lupus erythematosus [80]. The average diameter of the particles is 225 nm and
their structure is analogous to the previously reviewed. The essential difference lay in the drug
loaded: Mycophenolic acid (MPA) as immunosuppressant. However, in addition to the efficacy trials
on NZB/W F1 mice, the drug delivery system has been tested on C57BL/6 murine models (not
susceptible to lupus) to evaluate the hematological and organ toxicity; as the control were adopted
animals administered with PBS. The animals were exposed to four daily doses of nanolipogels MPA
loaded and the analyses were carried out 4, 7, and 14 days later. Clinical parameters related to renal
function, hepatic function, and the complete blood counts presented all values within the reference
ranges. An enhanced accumulation in the kidneys was detected for the nanogel, but again, no signs of
renal or hepatic toxicity were detectable. As an additional note on the results, the treatment of lupus
erythematosus by this nanohybrid carrying 5–azacytidine showed an encouraging regression of the
disease [107].
A further contribution is the work of Ki Dong and colleagues, who developed PEGylated
liposomes containing a heparin-pluronic physical nanogel for the delivery of ribonuclease A [81].
The liposomes size ranges from 200 to 300 nm and their preparation involve phosphatidylcholine
PEGylated with chains of 4000 Da. The peculiarity of this work is the easy nanolipogel preparation; the
whole procedure is indeed quite simple and driven by self-assembly. The liposome reconstitution from
dry phospholipids and cholesterol occurs by sonication in an aqueous solution that already contains
ribonuclease and the heparin–pluronic previously prepared nanogel (Figure 10). Subsequently, the
material that was not encapsulated is removed by centrifugation. It is worth citing that authors
describe in detail the synthesis of PEGylated phosphatidylcholine.
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effect and the non-toxicity of the system, although the experiments were performed at a single 
concentration of 100 μg/mL. 
In 2018, Zhang et al. prepared various liposome-camouflaged nanogels [82,108,109], adopting 
for all systems the PEGylation strategy with chains of 2000 Da grafted on the lipidic shell. Their most 
distinguished work [82] reports the drug delivery combined with the photothermal effect. In this 
case, the embedded nanogel is a typical thermoresponsive isopropyl-acrylamide polymer, inserted 
in the lipid vesicle through a quite sophisticated technique. As a first step, the liposomes were 
assembled in the aqueous gel precursor solution, together with monomers and radical initiator. Then, 
once the vesicles have been formed, a membrane-impermeable radical inhibitor is added and the 
polymerization is carried out (Figure 11); however, the nanogel is formed only inside liposomes, 
where the reaction is not inhibited.  
Figure 10. The PEGylated nanolipogel containing heparin-pluronic nanogel loaded with RNase.
Adapted by permission from Springer Nature: Macromolecular Resear h [81], Copyright 2015.
The nanohybrid was tested in vitro on mouse fibroblasts NIH3T3, showing the drug delivery effect
and the no -toxicity of the ystem, although the experiments were performed at a single concentration
of 100 µg/mL.
In 2018, Zhang et al. prepared various liposome-camouflaged nanogels [82,108,109], adopting
for all systems the PEGyl tion strategy w th chains f 2000 Da gr ft on the lipidic shell. Their most
distinguished work [82] reports the drug delivery combined with the ph to rmal effect. In t is case,
the embedded nanogel is a typical t ermoresponsive isopropyl-acrylamide polymer, inserted in the
lipid vesicle through a quite sophisticated technique. As a first step, the liposomes were assembled
in the aqueous gel precursor solution, together with monomers and radical initia or. Then, once the
ve icles have been formed, a membrane-impermeable radical inhibit r is added and the polymerization
is carried out (Figure 11); however, the nanogel is formed only inside liposomes, where the reaction is
not inhibited.
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In a slight variation proposed by the sa e authors [109], the nanogel was prepared by adopting
cysteine di ethacrylate as redox responsive disulfide crosslinker. Thus, the nanohybrid release is
triggered by the presence of glutathione inside the cells. The other components of the structure
have been left substantially unchanged and the in vitro bioco patibility/he oco patibility ere
unaffected by this variation.
4. Zwitterionic Nanogels
A different and relatively recent technique to extend the circulating half-life of nanosystems
is represented by the decoration with zwitterionic structures. This type of functionalization does
not present specific synthetic difficulties and may provide a valuable alternative to the strategy of
PEGylation [110], even on hybrid nanogel, as disclose by the positive outcomes herein collected.
The idea is based on the otable a tifouling properties of zwitterionic s rfaces [111], which also
reproduces a direct imitation of the character of cell membranes. The presence of both positive and
negative charges close to each other along the whole structure lead to a hydrophilic and strongly
polar surface, consequently, a stable layer of water molecules is created around the nanoparticle.
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This aqueous layer is firmly structured and reveals a high efficiency in preventing the non-specific
protein adsorption [112]. Moreover, the zwitterionic structure maintains a net charge balanced with a
zeta potential near to zero, limiting the electrostatic interactions with proteins [113].
One of the first applications of such strategy to hybrid nanogels has been achieved by Jiang and
colleagues in 2011 [83]. Their work describes the encapsulation of Fe3O4 magnetic nanoparticles
in a nanogel based on carboxybetaine methacrylate (CBMA) and cystine bisacrylamide as a
reduction–sensitive crosslinker (Figure 13). Besides, through the acid groups of carboxybetaine,
the nanohybrid was further decorated with a RGD peptide to increase the uptake by target cells. As a
model drug was inserted as a fluorescein-labeled dextran, it was easily traceable and commercially
available. The release experiments in the presence of dithiothreitol revealed an expulsion of about 80%
of the fluorescent load within 24 h, while in the absence of the reducing agent, a release lower than
5% was observed at the same time lapse. The degradation of the nanogel was also confirmed by the
magnetic resonance imaging experiments and DLS analyses. These showed the nanogel particles of
~110 nm disappear after the addition of dithiothreitol, to be replaced by nanoparticles of ~10 nm, the
diameter of the previously embedded Fe3O4 particles. Biological tests were performed on macrophages
and on HUVEC cells, reporting in both cell lines, no observable cytotoxicity at the concentrations
of 1–30 ppm of iron content, although the iron content per mg of nanogel was reported. Authors
further mention that, after lyophilization, the product was redispersed in PBS obtaining a reconstituted
nanogel with an unaltered dimension (110 nm).
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Figure 13. Schematic passages for the preparation of zwitterionic hybrid nanogel. Reprinted from 
Reference [83], Copyright (2011), with permission from Elsevier. 
One more work of Jiang combine the zwitterionic feature with a singular aspect, the “softness” 
of the particles, to produce a nanogel with a longer circulating time and lower splenic accumulation 
[84]. The study of biomechanical properties of the nanoparticles, as a leading aspect of their 
physiological behavior is indeed another relevant issue, recently highlighted by noteworthy works 
[47,114]. While it concerns an aside topic, it is worthwhile to simply recall the direct linkage between 
elastic module and circulating time of erythrocytes [115], as well as the example of a microgels 
mimicking the red blood cells rheology to acquire an extended half-life [116]. 
In the described case [84], the authors prepared in different parallel nanogels, all carrying gold 
nanoparticles as a core and poly(carboxybetaine) as a polymer, but containing different amounts of 
the crosslinker carboxybetaine dimethacrylate (Figure 14a). This crosslinker, together with the 
monomer, ensures the complete zwitterionic nature of the nanogel. The various batches of 
nanohybrids share the same diameter, around 120 nm; however, possessing different stiffness, they 
provide different biological outcomes. The in vivo tests on animal models indicate the direct 
correlation between higher crosslinker density and longer circulation half-life, confirming the 
proposed strategy. A simple assay, which is still immediate, has been obtained by filtering the 
nanogel particles through a 0.22 μm syringe filter (Figure 14b), although the hydrodynamic diameters 
were the same, the response to filtration was very different. 
Figure 13. Schematic passages for the preparation of zwitterionic hybrid nanogel. Reprinted from
Reference [83], Copyright (2011), with permission from Elsevier.
One more work of Jiang combine the zwitterionic feature with a singular aspect, the “softness” of
the particles, to produce a nanogel with a longer circulating time and lower splenic accumulation [84].
The study of biomechanical properties of the nanoparticles, as a leading aspect of their physiological
behavior is indeed another relevant issue, recently highlighted by noteworthy works [47,114]. While it
concerns an aside topic, it is worthwhile to simply recall the direct linkage between elastic module and
circulating time of erythrocytes [115], as well as the example of a microgels mimicking the red blood
cells rheology to acquire an extended half-life [116].
In the described case [84], the authors prepared in different parallel nanogels, all carrying gold
nanoparticles as a core and poly(carboxybetaine) as a polymer, but containing different amounts of the
crosslinker carboxybetaine dimethacrylate (Figure 14a). This crosslinker, together with the monomer,
ensures the complete zwitterionic nature of the nanogel. The various batches of nanohybrids share
the same diameter, around 120 nm; however, possessing different stiffness, they provide different
biological outcomes. The in vivo tests on animal models indicate the direct correlation between higher
crosslinker density and longer circulation half-life, confirming the proposed strategy. A simple assay,
which is still immediate, has been obtained by filtering the nanogel particles through a 0.22 µm syringe
filter (Figure 14b), although the hydrodynamic diameters were the same, the response to filtration was
very different.
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nanogel and with bare gold nanoparticles (nanogel concentration: 42 µg/mL, corresponding to 5 ppm
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Another type of nanoparticle efficiently involved in a zwitterionic nanogel is represented by
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Figure 15. Monomer structure and zwitterionic nanogel-carbon dots assembly. Reprinted from
Reference [85], Copyright (2016), with permission from Elsevier.
Different quantities of the crosslinker (carbon dots), from 0.5% to 10% (w/w), have been tested
resulting in nanoparticles of different diameters, from near 170 to 114 nm. This effect is ascribable
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to two factors: The higher entangling degree, which lead to a lower gel swelling [118,119], and the
presence of multiple nucleation centers during the polymerization, resulting in the formation of
smaller nanoparticles [120]. In the present study [85], authors used the smallest particles for all the
experiments, rationalizing the choice on the basis of their optimal size [121]. As an experiment to
validate the interactions with proteins and general stability in physiological media, the nanohybrid
was incubated for 24 h in 5% human plasma fibrinogen or in 5% bovine serum albumin solutions
with PBS, not revealing in either case an increase of the hydrodynamic size. In addition, in vitro
tests on NIH/3T3 fibroblasts revealed a good biocompatibility of the structure; the cell viability was
around 90% after 24 h of incubation at a concentration 1 mg/mL. Further biological tests were also
performed on SKOV3 ovarian cancer cells to prove the targeting effect of the folic acid decoration on
cellular uptake.
5. Challenges and New Perspectives for Hybrid Nanogels
Nanogels are 3D constructs in colloid form with a crosslinked polymeric scaffold, typically
stable in aqueous media. Due to the high complexity of these systems and to the high need of
reproducible devices, a proper understanding of these structures is fundamental [122,123]. Respect
to other nanosystems, the strength of hybrid nanogels is their ability to improve circulating lifetimes
and bioavailability of the carried drugs, joined with a wide versatility of the structures. The capability
of nanogels to be variously decorated with molecules and polymeric chains, their elastic structure,
their possible zwitterionic surface, and the possibility to be easily combined with other nanostructures,
make them a very suitable candidate to overcome the current limitations of many drug delivery
systems. Possible weaknesses are still present, a price for their versatility may be identified in the
polymerization, the synthetic step required for their preparation, absent for commercially available
inorganic or metal nanostructures and pivotal to obtain a proper nanohybrid. Besides, compared to
“hard” scaffolds like carbonaceous nanomaterials, their storage may require delicate steps, such as the
lyophilization, to prepare a stable and reconstitutable product.
Concerning their medical application, nanogels are still present in clinical trials, mainly focused
on cholesterol–pullulan structures for cancer immunotherapy [124–128]. However, many challenges
still exist in order to widen their clinical development. First of all, the mechanisms and the pathways
of active intracellular uptake should be deeply investigated in order to understand their fate in living
organisms. The quick clearance by the immune system represents a classic problem for drug delivery
scaffolds, together with low selectivity in cell targeting and low efficiency to overcome biological
hurdles and barriers, such as the blood-brain barrier [71,129]. For this purpose, the easy traceability and
the adaptable properties of hybrid nanogels would bring a worthwhile contribution in the development
of experiments devised to acquire a more accurate knowledge of the biological mechanisms involved.
As observed, the tunable softness, the bioresorbable structures, and the different types of possible
decoration are features commonly achievable by nanogels, which may represent key variables for
understanding the biological responses.
In addition, safety concerns should also be taken into account. Nanotoxicity in the last years is
working in parallel with nanomedicine in the aim of understand the possible negative impact between
nano-objects and biological systems. Preliminary studies have actually indicated that, in many cases,
nanosystems contributed to inflammation, damage, and unwanted cell uptake [130,131]. In this respect,
although several efforts should still be involved to understand the factors behind toxicity, we here
observed many strategies conceived by nanogels to minimize these drawbacks.
The reproducible and consistent manufacturing of nanosystems is another relevant question that
should be solved. It is commonly known that the scale up of nano-objects production represent a
considerable challenge since, by increasing the scale, the formation of novel surface is less-favored
respect to the bulk. Moreover, given the presence of multiple reaction conditions, as the use of organic
solvents, emulsification, ultrasound and homogenization, is fundamental to the identification of the
main parameters to obtain reproducible, storable (e.g., upon freeze-drying), and fully reconstitutable
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nanogels. High attention should be paid to the reproducibility of the process to ensure that the
characteristics of the colloid remain the same during the scale up procedure, avoiding instability or
aggregation before use. Ultimately, the sterilization methods may also influence the characteristics of
the product, affecting mechanical properties and degradation [132,133], and from the perspective of
clinical application should be adequately considered.
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